We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$713M
Cap. Flow
+$1.03B
Cap. Flow %
77.19%
Top 10 Hldgs %
46.07%
Holding
196
New
82
Increased
39
Reduced
17
Closed
45

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$20M
2
XLRN
Acceleron Pharma
XLRN
+$18.6M
3
TARA icon
Protara Therapeutics
TARA
+$12.9M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$12M
5
VSTM icon
Verastem
VSTM
+$11M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$5.72M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.63M
3
TGTX icon
TG Therapeutics
TGTX
+$3.51M
4
KALA icon
KALA BIO
KALA
+$3.39M
5
ARQL
Arqule Inc
ARQL
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 19.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
76
DELISTED
Cymabay Therapeutics
CBAY
$3.5M 0.26%
+2,366,850
New +$3.97M
MYOV
77
DELISTED
Myovant Sciences Ltd.
MYOV
$3.4M 0.26%
+450,000
New +$5.05M
BLUE
78
CALL
DELISTED
bluebird bio
BLUE
$3.22M 0.24%
+5,404
New +$5.27M
AUPH icon
79
Aurinia Pharmaceuticals
AUPH
$1.91B
$3.17M 0.24%
218,771
-262,333
-55% -$4.63M
ICPT
80
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.15M 0.24%
50,000
-14,900
-23% -$1.34M
BPMC
81
CALL
DELISTED
Blueprint Medicines
BPMC
$2.92M 0.22%
+50,000
New +$3.22M
KYNB
82
PUT
Kyntra Bio
KYNB
$27.2M
$2.78M 0.21%
+3,200
New +$3.18M
INSM icon
83
Insmed
INSM
$21.4B
$2.77M 0.21%
+172,919
New +$4.1M
OTIC
84
DELISTED
Otonomy, Inc.
OTIC
$2.69M 0.2%
1,367,271
+300,000
+28% +$925K
MDGL icon
85
Madrigal Pharmaceuticals
MDGL
$10.8B
$2.69M 0.2%
40,334
-4,436
-10% -$370K
RIGL icon
86
Rigel Pharmaceuticals
RIGL
$681M
$2.62M 0.2%
168,053
+133,053
+380% +$2.83M
CLVS
87
DELISTED
Clovis Oncology, Inc.
CLVS
$2.62M 0.2%
+411,918
New +$3.3M
BBIO icon
88
BridgeBio Pharma
BBIO
$15.7B
$2.55M 0.19%
+87,900
New +$2.73M
ASMB icon
89
Assembly Biosciences
ASMB
$498M
$2.33M 0.18%
13,122
– –
BTAI icon
90
CALL
BioXcel Therapeutics
BTAI
$24.9M
$2.31M 0.17%
+6,456
New +$2.32M
NTLA icon
91
Intellia Therapeutics
NTLA
$1.49B
$2.26M 0.17%
+184,989
New +$2.49M
ARVN icon
92
CALL
Arvinas
ARVN
$518M
$2.26M 0.17%
56,100
+53,000
+1,710% +$2.48M
ASMB icon
93
PUT
Assembly Biosciences
ASMB
$498M
$2.23M 0.17%
12,500
– –
CASI
94
DELISTED
CASI Pharmaceuticals
CASI
$2.12M 0.16%
+103,991
New +$2.48M
MGNX icon
95
MacroGenics
MGNX
$235M
$2.1M 0.16%
360,030
+350,000
+3,490% +$3.18M
NERV icon
96
CALL
Minerva Neurosciences
NERV
$185M
$2.06M 0.15%
42,700
+33,387
+358% +$2.01M
RLMD icon
97
Relmada Therapeutics
RLMD
$557M
$1.88M 0.14%
+55,172
New +$2.22M
INO icon
98
PUT
Inovio Pharmaceuticals
INO
$55.7M
$1.86M 0.14%
+20,833
New +$1.28M
ADMA icon
99
ADMA Biologics
ADMA
$1.96B
$1.81M 0.14%
+630,000
New +$2.18M
AGTC
100
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.79M 0.13%
545,884
+345,000
+172% +$1.82M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Ikarian Capital held 196 positions worth $1.33B, up 115% from $617M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ikarian Capital deployed $1.03B of net new capital in Q1 2020, opening 82 new positions and adding to 39 existing holdings. Its largest new stake was Zogenix, Inc.: 549,459 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 16% a quarter earlier.

On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $4.63M trimmed.

  • Ikarian Capital's largest Q1 2020 buy was Zogenix, Inc.: 549,459 shares worth $13.6M.
  • Ikarian Capital added most to Protara Therapeutics in Q1 2020, an estimated $12.9M increase.
  • Ikarian Capital's biggest Q1 2020 reduction was Aurinia Pharmaceuticals, cutting an estimated $4.63M.
  • Ikarian Capital fully exited Aptose Biosciences, Inc. in Q1 2020, selling an estimated $5.72M.
  • Ikarian Capital's ten largest holdings make up 46% of its $1.33B portfolio in Q1 2020.
  • Ikarian Capital opened 82 new positions and closed 45 in Q1 2020.
  • Ikarian Capital's portfolio value rose 115% quarter-over-quarter to $1.33B.

Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.